Capricor Therapeutics (NASDAQ:CAPR) Shares Down 5.2% – Should You Sell?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares dropped 5.2% during mid-day trading on Wednesday . The stock traded as low as $13.21 and last traded at $12.99. Approximately 306,551 shares traded hands during trading, a decline of 77% from the average daily volume of 1,325,683 shares. The stock had previously closed at $13.70.

Wall Street Analysts Forecast Growth

CAPR has been the topic of a number of recent analyst reports. Cantor Fitzgerald raised their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Tuesday. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Down 10.1 %

The business’s fifty day moving average is $14.40 and its 200-day moving average is $13.93. The company has a market cap of $560.19 million, a PE ratio of -11.65 and a beta of 4.08.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently modified their holdings of the business. Summit Investment Advisors Inc. raised its holdings in Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after buying an additional 2,947 shares during the period. Virtus ETF Advisers LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter valued at about $68,000. AlphaQuest LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund increased its holdings in Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 5,000 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.